ALMS

Alumis Inc.

Healthcare
Biotechnology
$1.13B market cap

Forecast run · Sep 14, 2026Upside rank 43 of 3,136

Model Signal

ForecastQ Daily Probabilities

82.2%

28.9%

60.0%

Analyst Consensus

Recommendation2.13/5 Buy

Last price$9.18

Price target$29.57

Implied move+222.1%

Analysts8

ForecastQ Portfolios

ALMS is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.